key: cord-0910741-2fblfnjt
authors: Wongboonsin, Janewit; Shah, Sujal I.; Marty, Francisco M.; Mount, David B.; Rennke, Helmut G.; Murakami, Naoka
title: Osmotic tubulopathy in a patient with COVID-19 treated with remdesivir
date: 2021-05-12
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.04.032
sha: a9ab81030ae311e33ee17e30a4baf0de3b93e1b0
doc_id: 910741
cord_uid: 2fblfnjt

nan

COVID-19 has posed unique challenges to nephrology. COVID-19-associated acute kidney injury (AKI) occurs in as high as 36.6% of patients S1 , with the most common etiology being acute tubular injury due to hemodynamic changes and a pro-inflammatory milieu. In addition to acute tubular injury, patients with COVID-19 can also develop a variety of glomerular pathologies including primary podocytopathies and immune-mediated glomerular diseases (membranous nephropathy, lupus nephritis, anti-GBM disease). 1 Here, we report another pattern of tubular pathology related with COVID-19, osmotic injury associated with antiviral therapy.

A 33-year-old African American obese man with past medical history of poorlycontrolled type 2 diabetes mellitus and hypertension presented with left-sided abdominal pain for two days. His nasopharyngeal swab polymerase chain reaction (PCR) for SARS-CoV2 was positive. He was febrile, 38.1 °C (100.6 °F), tachycardic, 106 beats per minute, and blood pressure of 140/79 mmHg. Respiratory rate of 18 per minute, and oxygen saturation of 98% on room air. He was not in acute distress and was noted to have dry mucous membranes, clear respiratory sounds and no pedal edema. Computed tomography showed ground glass opacities in both lung bases compatible with COVID-19. Initial laboratory values showed acute kidney injury and hyponatremia ( Table 1 ). The patient was admitted for management of COVID-19 pneumonia and AKI.

After fluid resuscitation, creatinine further rose to 1.98 mg/dL, and hyponatremia worsened to 123 mmol/dL (127 mmol/dl, corrected with glucose). Urine studies suggested the syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( Table 2 ). The 24-J o u r n a l P r e -p r o o f hour urine collection confirmed the nephrotic range proteinuria: total protein of 12.8 g, with 8.6 g being albumin. The patient was obese (BMI 34.1) and has had poorly-controlled diabetes type 2 since age 20; hemoglobin A1c on admission was 12.1%, but his urine microalbumin was 677 mg/g creatinine one year prior to the admission, with associated baseline creatinine of 1.58 mg/dL. Renal ultrasound showed bilateral echogenic cortices with slightly enlarged kidneys (right kidney at 13.1 cm and left kidney at 13.4 cm) without evidence of hydronephrosis, and renal arteries and veins were patent.

On hospital day 6, the patient developed worsened bilateral opacities on chest X-ray with associated hypoxemia. A course of remdesivir and dexamethasone was started.

Remdesivir 200 mg was given intravenously for one dose, followed by 100 mg intravenously per day for four additional doses. Intravenous dexamethasone (10 mg per day) was given concomitantly for six doses. Blood glucose during the hospitalization was well-controlled by Serology for ANCA, anti-myeloperoxidase, anti-proteinase-3, anti-PLA2R antibodies, HIV, HBsAg, and HCV antibodies were all negative. Serum protein electrophoresis did not reveal evidence of M-spike. The serum-free light chain (FLC) ratio was 1.08 (kappa FLC 101.2 mg/L, lambda FLC 93.5 mg/L). The patient did not receive osmotic agents that are associated with osmotic tubulopathy, such as, but not limited to, IVIG, mannitol, low-molecular weight dextrans, radiologic contrast media, hydroxyethyl starch, excess glucose, methanol, and gelatin.

A kidney biopsy was performed to determine the etiology of proteinuria.

The sample consisted of renal cortex with 31 glomeruli, of which three were globally sclerosed, two were segmentally sclerosed, and 11 were hypoperfused. The non-sclerosed J o u r n a l P r e -p r o o f glomeruli were enlarged. While a classic example of a collapsing lesion is not seen on multiple levels examined, two glomeruli showed features strongly suggestive of segmental capillary collapse, with proliferating epithelial cells filling the Bowman's space ( Figure 1A ).

The mesangium was found to be expanded by the extracellular matrix, with few PAS-positive Ultrastructural examination revealed near-global and diffuse effacement of glomerular visceral epithelial cell foot processes ( Figure 1C ) and prominent cytoplasmic vacuolization of many proximal tubular epithelial cells ( Figure 1D ). Immunofluorescence and electron microscopy showed no evidence of paraprotein or immune complex deposition.

The immunohistochemical stain for SARS-CoV2 spike protein was negative in the kidney ( Figure 1E ).

The patient's oxygen requirement improved, and creatinine continued to improve to 1.65 mg/dL during the course of intravenous remdesivir therapy. The patient declined genetic testing of APOL1 risk alleles.

Our case highlights two histopathologic findings developing in the setting of SARS-CoV-2 infection, collapsing glomerulopathy and osmotic tubulopathy. Collapsing glomerulopathy is one of the characteristic glomerular pathologies reported in COVID-19, as seen also in other viral illnesses such as HIV and parvovirus B19, with Apolipoprotein L1 risk alleles being one of the risk factors (see Supplementary discussion). S2 In our patient, while the kidney biopsy showed a significant nodular diabetic glomerulosclerosis, the extent of proteinuria (12 g/day) was much more than that could be explained solely by the progression of diabetic kidney disease. The patient had only 677 mg/g of albuminuria one

year prior to this presentation, and COVID-19 infection likely worked as a second hit to cause diffuse podocyte injury, that resulted in massive proteinuria.

Osmotic tubulopathy is a finding characterized by cytoplasmic vacuolization, seen when proximal tubules become overwhelmed by the load of indigestible carbohydrates, such as sucrose, dextrans, hydroxyethyl starch, mannitol, and iodinated contrast media. 2 Remdesivir is a nucleotide analog that is used to treat patients with COVID-19 both in severe and mild disease. Due to its limited water solubility, remdesivir formulation contains sulfobutylether--cyclodextrin (SBECD) as a solubilizing carrier agent and we postulate that this contributed to osmotic tubulopathy in our patient.

First-generation cyclodextrin carrier agents, and -cyclodextrin, are cyclic oligosaccharides consisting of a macrocyclic ring of glucose subunits joined by -1,4 glycosidic bonds, and are exclusively excreted by the kidney. Due to their cyclic structure, they are resistant to hydrolysis by amylases and are associated with renal toxicity due to osmotic tubulopathy. 3 SBECD is a second-generation cyclodextrin, engineered to enhance ionization properties by adding a sulfobutyl ether group. 4 Preclinical animal study suggested that, while cytosolic vacuolation in kidney tubular epithelial cells was observed at as low as 160 mg/kg J o u r n a l P r e -p r o o f in rats, serum creatinine remained normal, and the histologic changes were reversible within 1 month after the last dose. 5 In a clinical safety study, healthy male volunteers received up to 200 mg/kg of SBECD without acute kidney injury.

The post-marketing studies of voriconazole provide the best available real-world safety data of SBECD, as its intravenous formulation contains 3. respectively. Given our patient's low eGFR of 43 mL/min/1.73m 2 , we chose the lyophilized form of remdesivir and he received a total of 600 mg of remdesivir, corresponding to a cumulative 18 g of SBECD over five days prior to the kidney biopsy. The exposure of 3-6 g of SBECD per day is well below the safety threshold of 250 mg/kg/day (i.e., for our patient, 25 g/day). A recent study looked at the safety of remdesivir in 11 patients with severe AKI, and reported no significant increase in serum creatinine after remdesivir treatment, S8 and another study also suggested the safety of remdesivir in 20 patients with eGFR <30 mL/min. 7 Our patient's serum creatinine continued to improve after initiation of remdesivir.

However, the significant vacuolization in proximal tubules is a clear and unmistakable structural sign of tubular injury. The differential diagnoses of vacuolar change seen in this case include the Armanni-Ebstein lesions characterized by larger cytoplasmic vacuolation in proximal tubules in the outer medullary regions, seen in the setting of extremely high glucosuria, and changes due to toxic or ischemic injury. Our patient had poorly-controlled diabetes and had significant glucosuria at the time of presentation, which could have been a J o u r n a l P r e -p r o o f contributory factor for osmotic tubular injury. Creatinine did not seem to serve as a sensitive enough biomarker for tubular injury in our case, or hyperfiltration mechanism might have compensated and masked the tubular injury. S9

In addition to collapsing glomerulopathy, the treatment of COVID-19 infection with remdesivir may be associated with osmotic proximal tubulopathy ( Table 3 ). The precise mechanism of the osmotic tubulopathy is unclear in our case, but is probably multifactorial, and clinicians should remain cautious in the use of remdesivir in patients with severe AKI or advanced chronic kidney disease. J o u r n a l P r e -p r o o f 

Kidney Biopsy Findings in Patients with COVID-19

Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes

Cyclodextrin nephrosis in the rat

Evaluation of intravenous voriconazole in patients with compromised renal function

Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)

Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis

Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? Clin Infect Dis